Search Results

There are 10283 results for: content related to: The VKORC1 and CYP2C9 genotypes are associated with over-anticoagulation during initiation of warfarin therapy in children

  1. VKORC1 and CYP2C9 Genotypes and Phenprocoumon Anticoagulation Status: Interaction Between both Genotypes Affects Dose Requirement

    Clinical Pharmacology & Therapeutics

    Volume 81, Issue 2, February 2007, Pages: 185–193, T Schalekamp, B P Brassé, J F M Roijers, E van Meegen, F J M van der Meer, E M van Wijk, A C G Egberts and A de Boer

    Version of Record online : 27 DEC 2006, DOI: 10.1038/sj.clpt.6100036

  2. Influence of CYP2C9 and VKORC1 Polymorphisms on Warfarin and Acenocoumarol in a Sample of Lebanese People

    The Journal of Clinical Pharmacology

    Volume 51, Issue 10, October 2011, Pages: 1418–1428, Ms Maria O. Esmerian, Dr Zahi Mitri, Dr Mohammad-Zuheir Habbal, Mr Eddy Geryess, Dr Ghazi Zaatari, Dr Samir Alam, Dr Hadi N. Skouri, Dr Rami A. Mahfouz, Dr Ali Taher and Dr Nathalie K. Zgheib

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270010382910

  3. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: Interaction between both genotypes affects overanticoagulation

    Clinical Pharmacology & Therapeutics

    Volume 80, Issue 1, July 2006, Pages: 13–22, Tom Schalekamp, Bjorn P Brassé, Janine F M Roijers, Youssef Chahid, Johanna H H van Geest-Daalderop, Hanneke de Vries-Goldschmeding, Eduard M van Wijk, Antoine C G Egberts and Anthonius de Boer

    Version of Record online : 3 JUL 2006, DOI: 10.1016/j.clpt.2006.04.006

  4. You have free access to this content
    Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users

    Journal of Thrombosis and Haemostasis

    Volume 10, Issue 4, April 2012, Pages: 606–614, T. I. VERHOEF, W. K. REDEKOP, M. M. BUIKEMA, T. SCHALEKAMP, F. J. M. VAN DER MEER, S LE CESSIE, J. A. M. WESSELS, R. M. F. VAN SCHIE, A. DE BOER, M. TEICHERT, L. E. VISSER, A. H. MAITLAND-VAN DER ZEE and ON BEHALF OF THE EU-PACT GROUP

    Version of Record online : 30 MAR 2012, DOI: 10.1111/j.1538-7836.2012.04633.x

  5. Genotypes Associated With Reduced Activity of VKORC1 and CYP2C9 and Their Modification of Acenocoumarol Anticoagulation During the Initial Treatment Period

    Clinical Pharmacology & Therapeutics

    Volume 85, Issue 4, April 2009, Pages: 379–386, M Teichert, RHN van Schaik, A Hofman, AG Uitterlinden, PAGM de Smet, BHCh Stricker and LE Visser

    Version of Record online : 18 FEB 2009, DOI: 10.1038/clpt.2008.294

  6. Genetic and Clinical Predictors of Warfarin Dose Requirements in African Americans

    Clinical Pharmacology & Therapeutics

    Volume 87, Issue 4, April 2010, Pages: 459–464, L H Cavallari, T Y Langaee, K M Momary, N L Shapiro, E A Nutescu, W A Coty, M A G Viana, S R Patel and J A Johnson

    Version of Record online : 13 JAN 2010, DOI: 10.1038/clpt.2009.223

  7. You have free access to this content
    An evaluation of gene–gene interaction between the CYP2C9 and VKORC1 genotypes affecting the anticoagulant effect of phenprocoumon and acenocoumarol

    Journal of Thrombosis and Haemostasis

    Volume 10, Issue 5, May 2012, Pages: 767–772, R. M. F. VAN SCHIE, A. M. V. BABAJEFF, T. SCHALEKAMP, J. A. M. WESSELS, S. LE CESSIE, A. de BOER, F. J. M. VAN DER MEER, E. VAN MEEGEN, T. I. VERHOEF, F. R. ROSENDAAL, A. H. MAITLAND-VAN DER ZEE and FOR THE EU-PACT STUDY GROUP

    Version of Record online : 2 MAY 2012, DOI: 10.1111/j.1538-7836.2012.04694.x

  8. You have free access to this content
    Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon

    British Journal of Clinical Pharmacology

    Volume 77, Issue 4, April 2014, Pages: 626–641, Talitha I. Verhoef, William K. Redekop, Ann K. Daly, Rianne M. F. van Schie, Anthonius de Boer and Anke-Hilse Maitland-van der Zee

    Version of Record online : 20 MAR 2014, DOI: 10.1111/bcp.12220

  9. You have free access to this content
    Impact of genetic factors (VKORC1, CYP2C9, CYP4F2 and EPHX1) on the anticoagulation response to fluindione

    British Journal of Clinical Pharmacology

    Volume 73, Issue 3, March 2012, Pages: 428–436, Karine Lacut, Estelle Ayme-Dietrich, Lenaick Gourhant, Elise Poulhazan, Marion Andro, Laurent Becquemont, Dominique Mottier, Gregoire Le Gal and Celine Verstuyft

    Version of Record online : 13 FEB 2012, DOI: 10.1111/j.1365-2125.2011.04095.x

  10. You have free access to this content
    Influence of proton pump inhibitors and VKORC1 mutations on CYP2C9-mediated dose requirements of vitamin K antagonist therapy: a pilot study

    British Journal of Haematology

    Volume 167, Issue 4, November 2014, Pages: 547–553, Sophie Brunner-Ziegler, Bernd Jilma, Dominic Magirr, Raute Sunder-Plassmann, Georgiana-Aura Giurgea, Alexandra Hammer, Christian Margeta, Martin Brunner, Renate Koppensteiner and Christine Mannhalter

    Version of Record online : 21 AUG 2014, DOI: 10.1111/bjh.13082

  11. Pharmacogenetics of Warfarin: Development of a Dosing Algorithm for Brazilian Patients

    Clinical Pharmacology & Therapeutics

    Volume 84, Issue 6, December 2008, Pages: 722–728, JA Perini, CJ Struchiner, E Silva-Assunção, ISC Santana, F Rangel, EB Ojopi, E Dias-Neto and G Suarez-Kurtz

    Version of Record online : 27 AUG 2008, DOI: 10.1038/clpt.2008.166

    Corrected by:

    Corrigendum: CORRIGENDUM: Pharmacogenetics of Warfarin: Development of a Dosing Algorithm for Brazilian Patients

    Vol. 85, Issue 4, 448, Version of Record online: 7 MAY 2008

  12. Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes

    Journal of Thrombosis and Haemostasis

    Volume 15, Issue 3, March 2017, Pages: 465–472, E. V. Baranova, T. I. Verhoef, G. Ragia, S. le Cessie, F. W. Asselbergs, A. de Boer, V. G. Manolopoulos, A. H. Maitland-van der Zee and for the EU-PACT group

    Version of Record online : 17 FEB 2017, DOI: 10.1111/jth.13615

  13. You have free access to this content
    New genetic variant that might improve warfarin dose prediction in African Americans

    British Journal of Clinical Pharmacology

    Volume 70, Issue 3, September 2010, Pages: 393–399, Hedi Schelleman, Colleen M. Brensinger, Jinbo Chen, Brian S. Finkelman, Mark J. Rieder and Stephen E. Kimmel

    Version of Record online : 27 MAY 2010, DOI: 10.1111/j.1365-2125.2010.03709.x

  14. Role of Pharmacogenomics in the Management of Traditional and Novel Oral Anticoagulants

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 31, Issue 12, December 2011, Pages: 1192–1207, Dr. Larisa H. Cavallari, Dr. Jaekyu Shin and Dr. Minoli A. Perera

    Version of Record online : 20 JAN 2012, DOI: 10.1592/phco.31.12.1192

  15. A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9

    Clinical Pharmacology & Therapeutics

    Volume 80, Issue 4, October 2006, Pages: 346–355, Lai-San Tham, Boon-Cher Goh, Anne Nafziger, Jia-Yi Guo, Ling-Zhi Wang, Richie Soong and Soo-Chin Lee

    Version of Record online : 22 OCT 2006, DOI: 10.1016/j.clpt.2006.06.009

  16. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin

    Journal of Clinical Pharmacy and Therapeutics

    Volume 37, Issue 2, April 2012, Pages: 232–236, L. K. Teh, I. M. Langmia, M. H. Fazleen Haslinda, H. A. Ngow, M. J. Roziah, R. Harun, Z. A. Zakaria and M. Z. Salleh

    Version of Record online : 20 APR 2011, DOI: 10.1111/j.1365-2710.2011.01262.x

  17. Warfarin Pharmacogenetics

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 28, Issue 9, September 2008, Pages: 1084–1097, Dr. Nita A. Limdi and Dr. David L. Veenstra

    Version of Record online : 6 JAN 2012, DOI: 10.1592/phco.28.9.1084

  18. The Missing Association: Sequencing-Based Discovery of Novel SNPs in VKORC1 and CYP2C9 That Affect Warfarin Dose in African Americans

    Clinical Pharmacology & Therapeutics

    Volume 89, Issue 3, March 2011, Pages: 408–415, MA Perera, E Gamazon, LH Cavallari, SR Patel, S Poindexter, RA Kittles, D Nicolae and NJ Cox

    Version of Record online : 26 JAN 2011, DOI: 10.1038/clpt.2010.322

  19. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements

    Clinical Pharmacology & Therapeutics

    Volume 79, Issue 4, April 2006, Pages: 291–302, Christina L. Aquilante, Taimour Y. Langaee, Larry M. Lopez, Hossein N. Yarandi, Jennifer S. Tromberg, Dagmara Mohuczy, Katherine L. Gaston, Cassandra D. Waddell, Mark J. Chirico and Julie A. Johnson

    Version of Record online : 16 APR 2006, DOI: 10.1016/j.clpt.2005.11.011

  20. Genetic Factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) Are Predictor Variables for Warfarin Response in Very Elderly, Frail Inpatients

    Clinical Pharmacology & Therapeutics

    Volume 87, Issue 1, January 2010, Pages: 57–64, E Pautas, C Moreau, I Gouin-Thibault, J-L Golmard, I Mahé, C Legendre, E Taillandier-Hériche, B Durand-Gasselin, A-M Houllier, P Verrier, P Beaune, M-A Loriot and V Siguret

    Version of Record online : 30 SEP 2009, DOI: 10.1038/clpt.2009.178